4 April 2018 ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
5 March 2018 ORYZON Announces Publication of Paper in Cancer Cell establishing the relevance of ORY-1001 as an antileukemic differentiating drug
19 February 2018 Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry
19 February 2018 ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2017
5 February 2018 ORYZON Appoints Clinical Development Leader Lori A. Kunkel, M.D., as a Scientific Advisor
29 January 2018 ORYZON announces First Patient In in ORY-2001 MS Phase IIA trial SATEEN and presents new data on ORY-2001 at the third annual ACTRIMS Forum 2018 in San Diego